Sylvester Comprehensive Cancer Center

  • VSMART - Antoni, Michael

  • Investigator:
    Michael Antoni
    RCname Email

    Coordinator:

    IRB: 20160525

    SDG: Population Sciences
    Disease Site(s):

    Breast

    Sponsor: Florida Biomedical Research Program

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    Stress Management Effects on Affective Status and Influenza Vaccine Response in Older Breast Cancer Patients.

    Eligibility Criteria - NCT03955991 *This information has been extracted from " www.clinicaltrials.gov"

  • RU115011 - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Onaidy Torres
    RCphone 3052436823

    IRB: 20170388

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: DOD

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    RU011501I: Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination with Folate Receptor Alpha Peptide Vaccine with GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients with Triple Negative Breast Cancer

    Eligibility Criteria - NCT03012100 *This information has been extracted from " www.clinicaltrials.gov"

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple

    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • C-610-01 - Hosein, Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20180763

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Breast,Bladder,Rectum,Soft Tissue,Melanoma, skin

    Sponsor: Agenus

    Enrolling Sites:

    Sylvester

    Title:

    C-610-01:A Phase 1a First-in-Human Study of Safety and Tolerability of ASV? AGEN2017 With QS-21 Stimulon® Adjuvant as a Single Agent in Subjects with Solid Tumor at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection

    Eligibility Criteria - NCT03673020 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20191076

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin

    Sponsor: EISAI

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101

    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • GSK3326595 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Lilia Curbelo
    RCphone 3052435803

    IRB: 20180040

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Breast,Brain and Nervous System,Non-Hodgkin Lymphoma

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Sylvester

    Title:

    GSK204653: A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma

    Eligibility Criteria - NCT02783300 *This information has been extracted from " www.clinicaltrials.gov"

  • A011502 - Mahtani, Reshma

  • Investigator:
    Reshma Mahtani
    RCname Email

    Coordinator:
    RCemailImg Evan Dadas
    RCphone 9544612163

    IRB: 20171116

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A011502: A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial

    Eligibility Criteria - NCT02927249 *This information has been extracted from " www.clinicaltrials.gov"

  • PACE - Mahtani, Reshma

  • Investigator:
    Reshma Mahtani
    RCname Email

    Coordinator:
    RCemailImg Evan Dadas
    RCphone 9544612163

    IRB: 20190016

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: DANA-FARBER CANCER INSTITUTE

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    17-101: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

    Eligibility Criteria - NCT03147287 *This information has been extracted from " www.clinicaltrials.gov"

  • DESTINY-Breast04 - Mahtani, Reshma

  • Investigator:
    Reshma Mahtani
    RCname Email

    Coordinator:

    IRB: 20190102

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: DAIICHI SANKYO

    Enrolling Sites:

    Deerfield
    Kendall
    Plantation
    Sylvester

    Title:

    DS8201-A-U303:A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2low, Unresectable and/or Metastatic Breast Cancer Subjects

    Eligibility Criteria - NCT03734029 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Colon,Breast-Female,Melanoma, skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • TTX-030-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20181017

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Colon,Pancreas

    Sponsor: TTH

    Enrolling Sites:

    Sylvester

    Title:

    TTX-030-001 : Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy inPatients with Lymphoma or Solid Tumor Malignancies

    Eligibility Criteria - NCT03884556 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190506 - Perez Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    Coordinator:
    RCemailImg Deborah Conte
    RCphone 9542101171

    IRB: 20190506

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: ASTRA ZENECA

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)

    Eligibility Criteria - NCT03997123 *This information has been extracted from " www.clinicaltrials.gov"

  • TROPICS-02 - Perez, Alejandra

  • Investigator:
    Alejandra Perez
    RCname Email

    Coordinator:

    IRB: 20190650

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: IMMUNOMEDICS

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens

    Eligibility Criteria - NCT03901339 *This information has been extracted from " www.clinicaltrials.gov"

  • EMR100036-002 - Samuels, Michael

  • Investigator:
    Michael Samuels
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160382

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Breast,Cervix Uteri,Stomach,Lung

    Sponsor: EMD

    Enrolling Sites:

    Sylvester

    Title:

    An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT02516813 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • NSABP B-51 - Takita, Cristiane

  • Investigator:
    Cristiane Takita
    RCname Email

    Coordinator:
    RCemailImg Zuzel Rodriguez
    RCphone 3052430124

    IRB: 20130534

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: NSABP

    Enrolling Sites:

    Deerfield
    Gables
    JMH
    Sylvester

    Title:

    RTOG1304: NSABP B51: A Randomized Phase III Clinical Trial Evaluating PostMastectomy Chestwall and Reginal Nodal XRT and PostLumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

    Eligibility Criteria - NCT01872975 *This information has been extracted from " www.clinicaltrials.gov"

  • A221505 - Takita, Cristiane

  • Investigator:
    Cristiane Takita
    RCname Email

    Coordinator:
    RCemailImg Zuzel Rodriguez
    RCphone 3052430124

    IRB: 20181215

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A221505: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction

    Eligibility Criteria - NCT03414970 *This information has been extracted from " www.clinicaltrials.gov"

  • MA.39: TAILOR RT - Takita, Cristiane

  • Investigator:
    Cristiane Takita
    RCname Email

    Coordinator:
    RCemailImg Zuzel Rodriguez
    RCphone 3052430124

    IRB: 20190405

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: CCTG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    CCTG MA.39: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

    Eligibility Criteria - NCT03488693 *This information has been extracted from " www.clinicaltrials.gov"

  • 201209135 - Neratinib - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Angie Denis
    RCphone 3052439535

    IRB: 20140485

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: WUSTL

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

    Eligibility Criteria - NCT01670877 *This information has been extracted from " www.clinicaltrials.gov"

  • DS8201-a-U105 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20180855

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Bladder

    Sponsor: DAIICHI SANKYO

    Enrolling Sites:

    Sylvester

    Title:

    DS8201-A-U105:A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer

    Eligibility Criteria - NCT03523572 *This information has been extracted from " www.clinicaltrials.gov"

  • 1280.18 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20181019

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: BOEHRINGER INGELHEIM

    Enrolling Sites:

    Sylvester

    Title:

    1280.18 : An Open Label, Phase Ib Dose-escalation Study Evaluating the Safety and Tolerability of BI 836845 and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive Breast Cancer, Followed by Expansion Cohorts

    Eligibility Criteria - NCT03099174 *This information has been extracted from " www.clinicaltrials.gov"

  • NATALEE (TRIO033) - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Angie Denis
    RCphone 3052439535

    IRB: 20181047

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: NOVARTIS

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    CLEE011O12301C (TRIO033) : A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negartive Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)

    Eligibility Criteria - NCT03701334 *This information has been extracted from " www.clinicaltrials.gov"

  • SWOG S1418 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Angie Denis
    RCphone 3052439535

    IRB: 20181122

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: SWOG

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With = 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

    Eligibility Criteria - NCT02954874 *This information has been extracted from " www.clinicaltrials.gov"

  • ATTCK-34-01 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20190286

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: UNUM THERAPEUTICS

    Enrolling Sites:

    Sylvester

    Title:

    ATTCK-34-01: A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies

    Eligibility Criteria - NCT03680560 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190505 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:

    IRB: 20190505

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: SEATTLE GENETICS

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer

    Eligibility Criteria - NCT03975647 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190673 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190673

    SDG: Breast Cancer
    Disease Site(s):

    Esophagus,Breast,Ovary,Other Female Genital,Kidney,Stomach,Colon,Lung

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190955 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:

    IRB: 20190955

    SDG: Breast Cancer
    Disease Site(s):

    Breast

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

    Eligibility Criteria - NCT03199885 *This information has been extracted from " www.clinicaltrials.gov"